Asensus Surgical, Inc.

Good day, and welcome to the Ascensus Surgical Incorporated 2022 Third Quarter Financial and Operating Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Mark Klossner. Please go ahead.

Good afternoon, everyone, and thank you for joining us for the Ascensus Surgical Third Quarter 2022 Business and Financial Update Conference Call. On the call with me today are Anthony Fernando, President and Chief Executive Officer, and Shamiz Rampertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business, including any impact from the COVID-19 pandemic and other geopolitical factors beyond our control. The company undertakes no obligation to update the information provided on this call. For a discussion of risks and uncertainties associated with the Ascensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2021 Form 10-K, filed in February 2022, and the Form 10-Q, expected to be filed later today, and any other filings we make with the SEC. During this call, we will also present certain non-GAAP financial information related to adjusted net loss attributable to common stockholders, and the adjusted net loss per common share attributable to common stockholders. Management believes that these non-GAAP financial measures taken in conjunction with U.S. GAAP financial measures provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP financial measures to compare our performance relative to forecast and strategic plans to benchmark our performance externally against competitors and for certain compensation decisions. Reconciliations from U.S. GAAP to non-GAAP results are presented in the tables accompanying our earnings release, which can be found in the investor relations section of our website. With that, it's my pleasure to turn the call over to Ascensus Surgical's President and Chief Executive Officer, Anthony Fernando.

Thanks, Mark, and thank you all for joining us today. Today, I will begin with discussing our recent performance and events. then Shamice will review our financial results. Following that, I will go over our third quarter performance and priorities for the balance of 2022 before turning to Q&A. Now I would like to provide an overview of our recent performance. We are pleased to see an accelerated expansion of the Senhance system install base this quarter with four new system initiations, two in Germany, one in Japan, one in the CIS region. Subsequent to the end of the third quarter, we announced an additional system placement in Germany, bringing the year-to-date total to five system initiations. We remain focused on increasing awareness of Senhans and educating the surgical community on its benefits by leveraging industry events. In September, We received the Society of Laparoscopic and Robotic Surgeons, or SLS, 2022 Innovation of the Year Award for our Intelligent Surgical Unit, or ISU. Each year, SLS recognizes the most innovative products that have a multidisciplinary application in minimally invasive surgery. We are incredibly proud of our team's commitment to enhancing clinical performance and very excited that the clinical community sees the tremendous value the ISU brings to the OR. We also participated in the 12th European Society of Pediatric Endoscopic Surgeons Annual Congress in Barcelona, Spain, in late September. Dr. Hamid Kakir, a pediatric surgeon at Maastricht University Medical Center in the Netherlands, gave an insightful presentation during the robotics master class focused on its success in pediatric procedures using Senta. As we continue to seek to drive global adoption, we recently moved into a new office in the heart of Tokyo, Japan, with a new showroom and state-of-the-art training facility. This is very exciting as we have grown our install base over the last few years in Japan and have seen great momentum with our clinical efforts in the country. As Japan is the number one laparoscopy market and the number two robotics market, we have seen that surgeons are eager to adopt digital laparoscopic technology, and we will continue to partner with new hospitals in order to facilitate these innovative procedures with this enhanced system. We have continued to add talent across our senior leadership team as we work to drive developments of performance-guided surgery and accelerate the adoption of SYNHANSE globally. Following the addition of a new Vice President of Medical Affairs and Professional Education, we recently appointed a new Vice President of Global Marketing to bolster our efforts to drive awareness of the platform among surgeons and hospital administrators. With that, I will turn the call over to Shamice for a financial update.